CN-121971418-A - Application of 1, 3-propylene diamine or pharmaceutically acceptable salt thereof in preparation of medicines for preventing or treating diabetes

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of 1, 3-propylene diamine or pharmaceutically acceptable salts thereof in preparation of medicines for preventing or treating diabetes. Experimental results show that 1, 3-propane diamine can obviously improve the random blood sugar and fasting blood sugar of type 2 diabetes mice, and 1, 3-propane diamine can obviously improve the insulin resistance of model mice. The invention uses 1, 3-propane diamine for improving the blood sugar of type 2 diabetes patients for the first time, obtains ideal treatment effect, provides a new treatment option for improving the blood sugar level for clinical application, and has extremely high application value and social benefit.

Inventors

• Jin Zirun
• LI JIAXING
• JIANG HUI
• Ai Yizhuo
• ZHU JUN

Assignees

• 北京大学第一医院(北京大学第一临床医学院)

Dates

Publication Date

20260505

Application Date

20260317

Claims (8)

1. Use of 1.1,3-propanediamine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of diabetes.
2. 2. The use according to claim 1, wherein the diabetes is type 2 diabetes.
3. 3. The use according to claim 2, wherein the medicament reduces the random and fasting blood glucose in a type 2 diabetic patient.
4. 4. The method of claim 2, wherein the agent has no effect on fasting weight and random weight in a type 2 diabetic patient.
5. 5. The use according to claim 2, wherein the medicament improves insulin resistance in a type 2 diabetic patient.
6. 6. The method of claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
7. 7. The method of claim 6, wherein the product is an oral dosage form.
8. 8. The method of claim 7, wherein the oral dosage form is a tablet, pill, oral liquid, capsule, syrup, drop pill, or granule.

Description

Application of 1, 3-propylene diamine or pharmaceutically acceptable salt thereof in preparation of medicines for preventing or treating diabetes Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of 1, 3-propylene diamine or pharmaceutically acceptable salts thereof in preparation of medicines for preventing or treating diabetes. Background Diabetes is a chronic metabolic disease characterized by an elevated blood glucose, and is largely classified into type 1, type 2, gestational diabetes, and the like. Among them, type 2 diabetes (T2 DM) is the most common type, and its central pathological features are insulin resistance and progressive insulin hyposecretion, resulting in the body not being able to effectively use glucose, and thus causing hyperglycemia. The disease is not only related to genetic susceptibility, but also closely related to life style such as obesity, lack of exercise, high calorie diet and the like, and pathogenesis involves complex interactions of multiple factors. As a significant public health challenge worldwide, the prevalence of type 2 diabetes continues to rise. According to the latest data issued by the world health organization, the total number of diabetics in the world is more than 4.6 hundred million, wherein the type 2 diabetics account for more than 90 percent, and the dominant position of the type 2 diabetics in the diabetes group is highlighted. This trend is particularly pronounced in some high income countries, and the risk of male onset is slightly higher than that of female, especially in the age group of 30-34 years old, reflecting the severe situation of type 2 diabetes mellitus rejuvenation. The long-term hazard of type 2 diabetes mellitus is remarkable, and various serious complications are easily caused if the blood sugar is poorly controlled. Microvascular complications include diabetic nephropathy (which may lead to renal failure), diabetic retinopathy (which may cause blindness) and diabetic neuropathy (which may be manifested as peripheral nerve pain or sensory loss), and macrovascular complications encompass cardiovascular and cerebrovascular diseases (such as coronary heart disease, stroke) and peripheral arterial diseases (which lead to limb ischemia and gangrene). These complications not only severely affect the quality of life of the patient, but also lead to high disability and mortality of the patient. For example, the life expectancy of type 2 diabetics is significantly reduced compared to healthy people, and about half of type 2 diabetics eventually die from cardiovascular complications, which place a heavy economic burden on the patient's home and also place a continuing burden on the social medical system. Worldwide, diabetes related medical expenditures are continually rising, particularly in developing countries where resources are limited, and their prevention, control and management have become priorities to address. Disclosure of Invention In order to solve the problem that the medicines for effectively treating diabetes (especially type 2 diabetes) in the prior art are insufficient, the inventor discovers that the 1, 3-propanediamine can obviously improve the blood sugar level for the first time, and provides a new treatment option for diabetes (especially type 2 diabetes). Specifically, the invention is realized through the following technical schemes: the invention provides application of 1, 3-propylene diamine or pharmaceutically acceptable salt thereof in preparing a medicament for preventing or treating diabetes. Alternatively, in the above application, the diabetes is type 2 diabetes. Alternatively, in the above application, the medicament reduces the random blood glucose and fasting blood glucose in a type 2 diabetic patient. Alternatively, in the above application, the drug has no effect on fasting body weight and random body weight of type 2 diabetics. Alternatively, in the above application, the medicament improves insulin resistance in type 2 diabetics. Alternatively, in the above application, the daily dosage of the drug is in the range of 60-90 mg for each patient. Alternatively, in the above application, the medicament further comprises a pharmaceutically acceptable carrier. Alternatively, in the above application, the "pharmaceutically acceptable carrier" of the present invention refers to a pharmaceutical carrier that is conventional in the pharmaceutical formulation field, and is selected from one or more of a filler, an adhesive, a disintegrant, a lubricant, a suspending agent, a wetting agent, a pigment, a flavoring agent, a solvent, and a surfactant. The filler of the present invention includes, but is not limited to, starch, microcrystalline cellulose, sucrose, dextrin, lactose, powdered sugar, dextrose, etc., the lubricant includes, but is not limited to, magnesium stearate, stearic acid, sodium chloride, sodium oleate, sodium lauryl sulfate, pol